ACTG Adds First Polyclonal Antibody to ACTIV-2 Outpatient Treatment Study for COVID-19
The AIDS Clinical Trials Group (ACTG), the largest global HIV research network, today announced the addition SAB-185, a polyclonal antibody therapy, to the COVID-19 outpatient treatment study, ACTIV-2 Outpatient Monoclonal Antibodies and Other Therapies Trial. ACTIV-2 includes both phase 2 and phase 3 evaluations of multiple investigational agents for treating early, symptomatic COVID-19 in a single trial. Rachel Presti, MD, PhD, associate professor of medicine is the principal investigator of the NIH – AIDS Clinical Trials Unit at Washington University School of Medicine and Medical Director of the Infectious Diseases Clinical Research Unit (ID CRU).
While there is widescale roll-out of COVID-19 vaccines, prevention and treatment will continue to play important roles in ending this pandemic. Treatment can have profound benefits, including shortening the duration of symptoms and potentially reducing or eliminating transmission of SARS-CoV-2 – the virus that causes COVID-19 – to others. By evaluating multiple agents across a single platform, ACTIV-2 aims to identify and advance treatments as expeditiously as possible.
See full press release.